| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 579.74M | 558.27M | 508.57M | 523.12M | 492.85M | 443.39M |
| Gross Profit | 177.51M | 172.58M | 152.03M | 148.13M | 118.88M | 108.14M |
| EBITDA | 68.86M | 64.80M | 60.96M | 60.10M | 38.77M | 31.16M |
| Net Income | 41.38M | 36.86M | 33.66M | 31.58M | 21.46M | 13.09M |
Balance Sheet | ||||||
| Total Assets | 283.86M | 273.21M | 293.90M | 293.32M | 294.18M | 274.29M |
| Cash, Cash Equivalents and Short-Term Investments | 22.69M | 15.35M | 62.72M | 57.43M | 48.83M | 57.84M |
| Total Debt | 66.54M | 69.75M | 67.02M | 78.90M | 105.54M | 112.52M |
| Total Liabilities | 140.23M | 138.91M | 128.10M | 143.36M | 180.72M | 193.63M |
| Stockholders Equity | 143.63M | 134.31M | 165.80M | 149.96M | 113.46M | 80.66M |
Cash Flow | ||||||
| Free Cash Flow | 31.19M | 27.29M | 27.05M | 22.91M | 14.09M | -4.75M |
| Operating Cash Flow | 53.58M | 45.67M | 35.90M | 41.86M | 40.01M | 16.08M |
| Investing Cash Flow | -22.38M | -18.38M | -8.86M | -19.04M | -25.92M | -20.82M |
| Financing Cash Flow | -70.71M | -74.66M | -21.73M | -13.61M | -22.13M | 40.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $504.62M | 13.62 | 26.29% | ― | 12.86% | 54.95% | |
67 Neutral | $2.07B | 66.01 | 46.40% | ― | 73.57% | 56.21% | |
65 Neutral | $542.89M | 51.85 | 10.27% | 2.41% | 0.68% | -67.84% | |
62 Neutral | $1.07B | 13.41 | 15.40% | ― | 19.88% | 51.03% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
46 Neutral | $253.26M | 42.22 | 13.73% | ― | 91.66% | 7.52% | |
45 Neutral | $201.80M | -0.62 | ― | ― | -4.93% | 18.65% |
On December 19, 2025, Ibex Limited announced several board and governance changes, appointing long-time associate and AI-focused executive Shuja Keen to fill a current vacancy on its Board of Directors and naming John Jones as Chair of the Board. Given that Jones is not deemed independent under Nasdaq rules, the Board also designated existing director Mingzhe (JJ) Zhuang as Lead Independent Director and Chair of the Corporate Governance Committee, changes that the company described as improving its governance structure and responding to prior shareholder feedback; all appointments took effect immediately and will run until the next annual general meeting or earlier termination in accordance with company procedures.
The most recent analyst rating on (IBEX) stock is a Hold with a $38.00 price target. To see the full list of analyst forecasts on IBEX stock, see the IBEX Stock Forecast page.
At the 2025 annual general meeting held on December 5, Ibex Limited’s shareholders approved several key proposals. These included setting the number of directors at a maximum of eight, electing directors to hold office until the next annual meeting or their resignation, allowing the board to fill any vacancies, and approving amendments to the 2020 Long-Term Incentive Plan. Additionally, Deloitte & Touche LLP was appointed as the auditor for the fiscal year ending June 30, 2026. Notably, Mr. Mohammed Khaishgi withdrew his nomination for re-election as a director for personal reasons, creating a vacancy on the board.
The most recent analyst rating on (IBEX) stock is a Hold with a $38.00 price target. To see the full list of analyst forecasts on IBEX stock, see the IBEX Stock Forecast page.
On November 20, 2025, Ibex Limited’s Board of Directors established a formal Nominating Committee to oversee the nomination of board members, a task previously handled by independent board members. This move aligns with Nasdaq Global Market rules and aims to address concerns raised by Institutional Shareholder Services Inc. and Glass Lewis & Co., LLC regarding the nominating process. The Committee’s responsibilities include identifying and recommending qualified director candidates and ensuring compliance with Nasdaq’s independence requirements. The Committee ratified past actions and recommended a slate of director candidates for the upcoming annual meeting on December 5, 2025, urging shareholders to vote in favor of the nominees.
The most recent analyst rating on (IBEX) stock is a Hold with a $38.00 price target. To see the full list of analyst forecasts on IBEX stock, see the IBEX Stock Forecast page.